Unknown

Dataset Information

0

Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma.

ABSTRACT:

SUBMITTER: Evens AM 

PROVIDER: S-EPMC9314600 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma.
| S-EPMC8297052 | biostudies-literature
Unknown Checkpoint Inhibition Therapy in Transplant-Ineligible Relapsed or Refractory Classic Hodgkin Lymphoma.
| S-EPMC8258137 | biostudies-literature
Unknown Transplant strategies in relapsed/refractory Hodgkin lymphoma.
| S-EPMC5897866 | biostudies-literature
Unknown Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma.
| S-EPMC7601361 | biostudies-literature
Unknown Phase II study of idelalisib, a selective inhibitor of PI3K?, for relapsed/refractory classical Hodgkin lymphoma.
| S-EPMC6246229 | biostudies-literature
Unknown High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
| S-EPMC8722342 | biostudies-literature
Unknown Management of relapsed/refractory classical Hodgkin lymphoma in transplant-ineligible patients.
| S-EPMC6536701 | biostudies-literature
Unknown Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.
| S-EPMC3862960 | biostudies-literature
Unknown A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.
| S-EPMC5927969 | biostudies-literature
Unknown Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma.
| S-EPMC5948762 | biostudies-literature